Measure of Plasma Tissue Factor to Predict a Venous Thromboembolism in Primitive Cancer of Lung

Does the Measure of the Plasma Tissue Factor Allow to Predict a Venous Thromboembolism Episode for Patients Presenting a Primitive Lung Cancer?

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02853188

Acronym

FT-KBP

Enrollment

315

Registered

2016-08-02

Start date

2014-12-04

Completion date

2018-12-20

Last updated

2019-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of Lung

Brief summary

The aim of the study is to evaluate if the plasma activity of the tissue factor at the time of the diagnosis of a lung cancer, before any treatment, or after the treatment of induction (surgery or two first cures of chemotherapy), can be a predictive factor of venous thromboembolism disease in the year which follows the diagnosis, independently of the other parameters.

Interventions

OTHERvenous thromboembolism

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients of more than 18 years old * Patients with cancer of lung diagnosis carried for less than 2 months and which were not handled yet, either by surgery or by chemotherapy, or by radiotherapy * Patients whose life expectancy is considered 3-month-old a superior * Patients having given writed consent * Patients affiliated to a national insurance scheme or benefiting from such a diet * Patients having received a treatment (processing) anticoagulating in preventive dose if this treatment was stopped at least 3 days before the 1st taking or patients not receiving an anticoagulating treatment (in case of curative treatment, the latter was before arrested at least 3 months

Exclusion criteria

* Patients having a hepatic disease with coagulation disorders * Patients under anticoagulants with dose guardian in 3 months preceding the study or presenting an active infection * Patients having a history of other cancer considered as cured and diagnosed for less than 5 years (with the exception of the patients operated for an in situ carcinoma of the neck of the womb or the patients having undergone the excision of a squamous-cell carcinoma)

Design outcomes

Primary

Measure	Time frame	Description
Venous thromboembolism occurence	2 years	—
Tissue factor	2 years	Tissue factor is measured by kinetic-chromogenic assay

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026